Form 4: Hims & Hers Chief Commercial Officer Michael Chi Reports Significant Stock Transactions

Hims & Hers Health, Inc.'s Chief Commercial Officer, Michael Chi, reported the exercise of Restricted Stock Units and subsequent sales of Class A Common Stock, primarily for tax obligations and under a pre-arranged trading plan.

Summary

• Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple transactions involving the company's Class A Common Stock.
• On June 13, 2025, Mr. Chi acquired 87,106 shares of Class A Common Stock through the exercise/conversion of Restricted Stock Units (RSUs).
• On the same date, June 13, 2025, 48,166 shares of Class A Common Stock were disposed of at a price of $55.48 per share to cover tax liabilities related to the RSU vesting.
• On June 17, 2025, an additional 17,102 shares of Class A Common Stock were sold at a price of $59.75 per share.
• All stock option exercises and sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2025.
• Following these transactions, Mr. Chi's direct beneficial ownership of Class A Common Stock stands at 278,654 shares.
• The filing also details the vesting of several tranches of RSUs, with various vesting start dates ranging from June 15, 2022, to June 15, 2025, all subject to a 4-year service-based vesting requirement.
• Mr. Chi also acquired 236 shares on May 20, 2025, under the Hims & Hers Health, Inc. 2020 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are sales by an insider, these are primarily for tax purposes related to RSU vesting and conducted under a pre-arranged 10b5-1 plan, which reduces the negative implication of insider selling. The vesting itself is a positive for the executive and reflects the company's compensation structure.

Positives

• Significant vesting of Restricted Stock Units (RSUs) indicates the fulfillment of long-term incentive compensation for a key executive.
• The acquisition of 87,106 shares through RSU conversion increases the executive's direct stake in the company before subsequent dispositions.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating planned and transparent insider activity rather than opportunistic selling.

Negatives

• The disposition of 48,166 shares for tax withholding and an additional 17,102 shares through sale represents a reduction in the Chief Commercial Officer's direct beneficial ownership.
• The sale of 17,102 shares at $59.75, while part of a plan, still represents an insider selling shares.

Future Outlook

The document primarily reports past and current insider transactions and does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the pre-scheduled vesting of remaining RSU tranches.

Industry Context

This Form 4 filing details routine insider stock transactions, specifically the vesting of equity compensation and subsequent sales, which are common occurrences for executives in publicly traded companies across all industries. It does not provide specific insights into broader industry trends or competitive dynamics within the telehealth or healthcare sectors.

Comparison to Industry Standards

• This document reports individual executive stock transactions, which are not typically compared to industry-wide financial or operational benchmarks.
• The nature of RSU vesting and subsequent sales for tax purposes or under 10b5-1 plans is standard practice for executive compensation across publicly traded companies, including those in the healthcare and technology sectors like Teladoc Health, Amwell, or GoodRx.

Related Party Transactions

• The reported transactions are related-party transactions as they involve an officer of the company trading in the company's securities. Specifically, the acquisition of shares from RSU vesting and the subsequent sales for tax purposes and under a 10b5-1 plan are direct dealings between the executive and the company's equity.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Commercial Officer, even if pre-planned, could be perceived by some shareholders as a slight negative, though the context of RSU vesting and tax obligations mitigates this. The transparency provided by the Form 4 filing and the 10b5-1 plan helps maintain investor confidence.
• Employees: The vesting of RSUs demonstrates the company's commitment to its equity compensation plans, which can be a positive for employee morale and retention.

Next Steps

• Continued vesting of remaining Restricted Stock Units (RSUs) for Michael Chi on future Company Quarterly Vesting Dates (March 15, June 15, September 15, December 15) as per the established 4-year service-based vesting schedules.

Key Dates

Keywords

Hims & Hers Health Inc., HIMS, SEC Form 4, Insider Trading, Stock Transactions, Restricted Stock Units, RSU Vesting, Rule 10b5-1 Plan, Officer Stock Sale, Michael Chi, Chief Commercial Officer, Equity Compensation